2,559,090 Shares in Neumora Therapeutics, Inc. $NMRA Purchased by ICONIQ Capital LLC

Key Points

• ICONIQ Capital acquired 2.56 million Neumora Therapeutics shares worth approximately $4.35 million, representing a 1.38% stake. Institutional investors collectively own 47.65% of the company.
• Neumora reported a quarterly loss of $0.23 per share, narrowly beating analyst expectations of a $0.24 loss. Analysts expect a full-year loss of approximately $0.85 per share.
• NMRA opened at $1.63, near its 50-day average of $1.60 and well below its $3.65 one-year high. Despite mixed analyst actions, the stock has a “Moderate Buy” consensus rating and a $6.57 average price target.

ICONIQ Capital LLC bought a new stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 2,559,090 shares of the company's stock, valued at approximately $4,350,000. ICONIQ Capital LLC owned 1.38% of Neumora Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. HBK Sorce Advisory LLC bought a new position in shares of Neumora Therapeutics during the 2nd quarter worth about $26,000. Hsbc Holdings PLC bought a new position in shares of Neumora Therapeutics during the fourth quarter valued at $27,000. Virtu Financial LLC acquired a new stake in shares of Neumora Therapeutics in the 3rd quarter valued at $31,000. Fred Alger Management LLC bought a new stake in shares of Neumora Therapeutics in the 4th quarter worth about $40,000. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Neumora Therapeutics in the 2nd quarter worth about $41,000. 47.65% of the stock is currently owned by hedge funds and other institutional investors.

Neumora Therapeutics Price Performance

NMRA stock opened at $1.63 on Monday. The company has a debt-to-equity ratio of 1.19, a current ratio of 4.50 and a quick ratio of 4.50. Neumora Therapeutics, Inc. has a one year low of $0.83 and a one year high of $3.65. The stock has a market cap of $306.28 million, a PE ratio of -1.33 and a beta of 2.75. The firm has a 50 day simple moving average of $1.60 and a two-hundred day simple moving average of $2.11.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.01. On average, analysts predict that Neumora Therapeutics, Inc. will post -0.85 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Daljit Singh Aurora sold 21,055 shares of the firm's stock in a transaction on Friday, August 21st. The stock was sold at an average price of $1.60, for a total transaction of $33,688.00. Following the completion of the transaction, the insider directly owned 48,750 shares in the company, valued at $78,000. This trade represents a 30.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 453,833 shares of company stock valued at $701,219 over the last 90 days. Insiders own 26.94% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Wall Street Zen raised Neumora Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 15th. Mizuho dropped their price objective on Neumora Therapeutics from $6.00 to $4.00 and set an "outperform" rating for the company in a report on Thursday, June 18th. HC Wainwright restated a "buy" rating on shares of Neumora Therapeutics in a research report on Tuesday, July 28th. Weiss Ratings lowered shares of Neumora Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, August 14th. Finally, Royal Bank Of Canada lowered their price target on shares of Neumora Therapeutics from $7.00 to $5.00 and set an "outperform" rating for the company in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Neumora Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $6.57.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora's product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source